Knight Therapeutics IncOTC Pink - Current Information:KHTRFView on Canadian Exchange
- LAST PRICE3.7300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.3800/ 2
- Ask / Lots3.8000/ 1
- Open / Previous Close--- / 3.7300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KHTRF |
|---|---|---|
| 03:51 ET | 200 | 3.73 |
Nov 14, 2024
Knight Therapeutics Announces Health Canada Approval for JORNAY PM(TM) to Treat Attention-Deficit Hyperactivity Disorder (ADHD), from 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
4:30PM ET on Thursday Nov 14, 2024 by Dow JonesDJ Knight Therapeutics Inc Price Target Cut to C$7.50/Share From C$8.00 by Raymond James, from 12:06PM ET on Thursday Nov 14, 2024 by Dow Jones
12:06PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
*DJ Knight Therapeutics 3Q Rev C$92.3M >GUD.T, from 7:31AM ET on Thursday Nov 07, 2024 by Dow Jones
7:31AM ET on Thursday Nov 07, 2024 by Dow JonesKnight Therapeutics Reports Third Quarter 2024, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 31, 2024
Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call, from 7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Knight Therapeutics Inc | 534.3M | --- | --- |
Company Information
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
Contact Information
- Headquarters
- 3400 De Maisonneuve Blvd WMONTREAL, QC, Canada H3Z 3B8
- Phone
- 514-484-4483
- Fax
- 514-481-4116
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $534.3M |
|---|---|
Revenue (TTM) | $348.6M |
Shares Outstanding | 100.8M |
Knight Therapeutics Inc does not pay a dividend. | |
Beta | 0.52 |
EPS | $-0.30 |
Book Value | $7.38 |
P/E Ratio | --- |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | 26.9x |
Operating Margin | 0.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
